FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Tag: Novartis
All
LatestSorry, No Posts Found
All
Latest
AI Model Identifies Melanoma With 94.5% Accuracy Using Images and Patient Data
The research team trained the system on more than 33,000 dermoscopic images paired with clinical metadata.
